The shortage-based legal exemption that underpinned widespread compounded semaglutide availability is no longer active for either 503A pharmacies or 503B outsourcing facilities Compounded GLP-1 programs operating today must navigate a legal framework that includes restrictions on compounding drugs that are commercially available drugs - meaning the compounding pharmacy's specific formulation, documentation, and prescriber individualization process matters for legal compliance The FDA still permits compounding under 503A for individual patient-specific prescriptions that involve a prescriber-documented "significant difference" from the commercially available product - but that requires specific clinical justification, not just a standard intake form Availability of specific compounded GLP-1 formulations may be affected by FDA enforcement actions, pharmacy-specific compliance status, and ongoing regulatory developments in this space None of this means compounded GLP-1 programs are operating illegally
A Retrospective Observational Study
Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, Morley TC, Yeo GS, Reimann F, and Gribble FM
This simple, non-greasy option fits into a streamlined regimen without requiring extra steps
(1968) breaks wheat (hexaploid) MacKey (1968) translocations insect Drosophila melanogaster Nakao & Auerbach (1961) small deletions insect Drosophila melanogaster Fahmy & Fahmy (1970) (min) ---------------------------------------------------------------------------------------- Table 5
A plan that treats them as one thing tends to overcorrect one and ignore the other
